GlioSeq® - NGS Panel for Brain Tumors

GlioSeq - NGS Panel for Brain Tumors
GlioSeq® is a next generation sequencing test to assist in diagnosis, prognostication and treatment of adult and pediatric CNS tumors.

GlioSeq Advantage

  • Adult & Pediatric CNS Tumors
  • Small Sample Size
  • Fast Turnaround Time

Test Details

  • GlioSeq v2 is utilizing an amplification-based targeted next generation sequencing of DNA and mRNA
  • It is strategically designed to sequence clinically relevant genes for mutations in 30 CNS-tumor-related genes, copy number changes in 24 genes, and multiple structural alterations, including BRAF, NTRK1-3, FGFR3, YAP1, and RELA fusions, and EGFRvIII mutation.
  • It can be berformed on small stereotactic brain biopsies and resected FFPE tumor specimens
  • It has fast turnaround time (7-10 days)
  • GlioSeq aids in the diagnosis of both adult and pediatric CNS tumors, including glioma, medullosblastoma, meningioma, and ependymoma

Genes Assayed by GlioSeq

Background

Examples of GlioSeq Reports

Specimen Requirements and Shipping Instructions